Oncozenge ONCOZ.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker ONCOZ.ST. It has been listed since 12 February 2021. In the fiscal year to 31 December 2025, it reported revenue of SEK 2.7m and a net loss of SEK 15.9m. At that date it held total assets of SEK 15.3m and shareholders' equity of −SEK 587,000.

OncoZenge AB operates as a pharmaceutical company. The company is headquartered in Bromma, Stockholm. The company went IPO on 2021-02-12. OncoZenge's vision is to improve the quality of life for patients with severe oral pain, for example caused by radiotherapy or chemotherapy in the treatment of cancer. The firm works on the introduction of its project BupiZenge. Its strategic and operational work focuses on the development of BupiZenge, which is a formulation of bupivacaine in the form of a lozenge. BupiZenge meets a need for pain relief in the mouth and throat, for example associated with oral mucositis, a serious complication after radiation or other cancer treatment. Preparations for registration establishment clinical studies are ongoing.

Figures and description from our data supplier, not checked against the company's own report.

• Pirkko Sulila Tamsen, PhDChief Executive Officer, since 2020
• Mark BeveridgeChief Financial Officer
• Cindy Wong, MD, PhDChief Marketing Officer, since 2020
• Anna LjungChairman, since 2020
• Hilde FurbergDirector, since 2020
• Mattias Klintemar, MBADirector, since 2020
• Torben Mogensen, MDDirector, since 2020

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.